UAE Over the past few decades, the UAE has worked hard to attract top global talent to fill the gaps that its small local population was unable to. While the high salaries on offer were previously the main attractor to the country, with workers often staying for a couple of years…
Global After a 12-year stint at Sanofi, Bill Sibold is leaving Big Pharma to join the Pennsylvania-based biotech Madrigal Pharmaceuticals as CEO. Sibold, no stranger to ground-breaking launches, having brought the blockbuster Dupixent to market, will be coming onboard just ahead of what looks to be a pivotal moment for Madrigal.…
Global Pfizer CEO Albert Bourla is the pharma executive with the biggest impact on social media, according to a new study. While busy industry leaders may not currently place social media engagement at the top of their priority lists, the study – published by specialist digital insights consultancy, Creation Healthcare –…
Global Ever since Novo Nordisk launched Wegovy two years ago, the company has struggled to meet the huge demand for its breakthrough weight loss drug and is yet to make it available in a larger range of markets. Following a recent launch in Germany, Novo Nordisk CEO Lars Fruergaard Jørgensen makes…
Belgium Janssen has the lofty aim of reaching USD 60bn dollars in sales by 2025, an 8bn increase on the 2021 figure, despite some high-profile losses of exclusivity and the spin-off of its consumer healthcare branch. This massive growth plan involves both existing products as well as new CAR-T and autoimmune…
Global Global biopharma is increasingly moving towards biologic medicines, which promise a greater impact on patient’s lives than the small-molecule drugs that preceded them, but which come with significant added costs and complexity. Against this backdrop, biologic drug developers are leaning evermore on experienced contract development and manufacturing organizations (CDMOs), of…
Belgium Maria Fernanda Prado highlights some of the lessons drawn from her extensive experience in emerging markets which remain applicable in her current role as Janssen’s managing director for the Benelux region. Belgium, the home country of Dr Paul Janssen, continues to be a significant part of the company’s global operations,…
Takeda Japanese-headquartered Takeda has been undergoing a transformation in recent years, becoming the global leader in rare diseases with the acquisition of Shire in 2018 and divesting ‘non-core’ assets in OTC and consumer goods. Here, four country and regional managers that PharmaBoardroom has spoken to in the past 12 months discuss…
UAE Amgen’s Mohammed Nasser casts his eye on some of the key trends affecting healthcare and the life sciences in the Middle East and Africa, including a significant maturity in uptake of digital and telehealth tools, better synchronisation of electronic medical records, and how artificial intelligence can be used to better…
Denmark Danish allergy specialist ALK will have a new CEO in 2024, with current incumbent Carsten Hellmann set to step down after a seven-year spell in the hot seat. Hellmann, 59, will be replaced by the comparatively youthful 45-year-old Peter Halling at the end of the year, which ALK Board Chairman…
Greece One of Greece’s leading domestic pharmaceutical companies, RAFARM has had a stellar recent history, including a momentous entry into the US market. Now looking to establish itself as one of Europe’s major players in ophthalmics and complex injectables, VP Aris Mitsopoulos highlights the key learnings from this US experience and…
USA During the ongoing BIO International Convention in Boston between June 5th and 8th, the US lobbying group has announced a new board chair in Ted Love as well as a new executive committee. Love is a longstanding BIO board director and the former President & CEO of Global Blood…
See our Cookie Privacy Policy Here